Lin’s extensive leadership experience expected to expand use of AposHealth’s revolutionary non-invasive treatment for knee pain nationwide
NEW YORK, Feb. 2, 2022 –Disruptive healthcare provider, AposHealth®, with locations in U.S., U.K., and Israel, names Cheri Lin as Chief Marketing Officer to help the company scale as it enters its next stage of growth.
AposHealth’s flagship solution, Apos®, is a revolutionary system that provides people suffering from musculoskeletal conditions such as chronic knee or lower back pain with a non-invasive and evidence-based solution to treat their pain in the comfort of their own homes. Apos® combines cutting-edge gait data science with proprietary, customized footwear. Together the system leverages biomechanics to redistribute the body’s weight from painful areas and re-educates the brain and muscles for healthier movement. The treatment consists of patients just wearing their Apos® for short periods of time each day while going about their regular routines.
“At this point in time we have proved out the value proposition of Apos® for payors, providers and patients. All stakeholders see Apos® as a game changer to treat MSK conditions,” says Cliff Bleustein, MD, MBA, President and CEO of AposHealth®. “With our fine-tuned infrastructure and regional success, we are happy to announce the addition of Ms. Lin to help build out AposHealth® nationally. Her expertise will help us catapult forward into our next phase of growth.”
Lin, who holds an MBA from Duke University, has a long history of providing transformational growth through business-to-business (B2B), direct-to-consumer (DTC), and business-to-business-to-consumer (B2B2C) marketing in the health and wellness sector—both among Fortune 50 companies and startups. During the course of her career, she successfully led Johnson & Johnson’s TYLENOL advertising strategy as well as the DTC campaign for its $4 billion cancer drug, PROCRIT. Lin also ignited the expansion of startup P4 Healthcare, resulting in year-over-year 4x-plus annual growth, and helped the company reach $75 million in revenue within four years.
Outside the office, Lin is passionate about health and wellness. She has received Apos® treatment for her own knee osteoarthritis, and within a short time went from having limited and painful movement to getting back to the gym and doing extensive workouts and even dance classes without pain. “I know firsthand how patients’ lives can become smaller and smaller thinking that pain and limitation is just a natural part of aging,” Lin says. “I’m committed to growing this market so that all patients with MSK conditions can benefit from Apos® and be able to live their lives to the fullest!”
We at AposHealth® are passionate about revolutionizing the treatment of musculoskeletal conditions by simply addressing peoples’ gait to help alleviate pain and help them move better and live better. Our flagship solution, Apos®, is FDA-cleared to temporarily reduce knee pain caused by osteoarthritis. It can also be used as a general wellness device to help patients live well with chronic lower back and hip pain. With a 96 percent satisfaction rate, over 110,000 patients treated, and dozens of peer-reviewed publications supporting the science behind Apos® as well as its clinical effect, this system—consisting of gait analysis, personalized foot-worn device, and a customized treatment plan—has helped patients with chronic knee, lower back, and hip pain worldwide move, live, and thrive.
Email: [email protected]
Mailing HQ Address: AposHealth® U.S. Office, C/O Studio, 300 Park Ave, 2nd floor, New York, NY 10022
Contact Number: 855-999-2767